Cymbalta and Sublocade drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Cymbalta (duloxetine hydrochloride) and Sublocade (buprenorphine). Common drug interactions include drug withdrawal syndrome among females and drug withdrawal syndrome among males.

The phase IV clinical study analyzes what interactions people have when they take Cymbalta and Sublocade. It is created by eHealthMe based on reports of 18 people who take the same drugs from the FDA, and is updated regularly.

What is Cymbalta?

Cymbalta has active ingredients of duloxetine hydrochloride. It is often used in depression. eHealthMe is studying from 154,973 Cymbalta users. Check the latest studies of Cymbalta.

What is Sublocade?

Sublocade has active ingredients of buprenorphine. eHealthMe is studying from 4,530 Sublocade users. Check the latest studies of Sublocade.



On Jul, 18, 2026

18 people who take Cymbalta and Sublocade together, and have interactions are studied.

Cymbalta and Sublocade drug interactions.

What are the common drug interactions of Cymbalta and Sublocade, by gender? *:

female:

  1. Drug withdrawal syndrome (interfere with normal social, occupational, or other functioning. are not due to another medical condition, drug use, or discontinuation)
  2. Injection site pain
  3. Maternal exposure during pregnancy (use of substance during pregnancy)
  4. Drug dependence
  5. Injection site erythema (redness at injection site)
  6. Muscle spasms (muscle contraction)
  7. Abdominal mass (localized enlargement or swelling in the human abdomen)
  8. Abdominal pain
  9. Blood lactate dehydrogenase increased
  10. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)

male:

  1. Drug withdrawal syndrome (interfere with normal social, occupational, or other functioning. are not due to another medical condition, drug use, or discontinuation)
  2. Injection site erythema (redness at injection site)
  3. Tooth infection
  4. Yawning (simultaneous inhalation of air and stretching of the eardrums, followed by exhalation of breath)
  5. Drug dependence
  6. Injection site irritation
  7. Injection site pruritus (severe itching at injection site)
  8. Joint swelling
  9. Oedema peripheral (superficial swelling)
  10. Rash macular (small, flat red spots)

What are the common drug interactions of Cymbalta and Sublocade, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Drug withdrawal syndrome (interfere with normal social, occupational, or other functioning. are not due to another medical condition, drug use, or discontinuation)
  2. Drug dependence
  3. Injection site erythema (redness at injection site)
  4. Injection site irritation
  5. Injection site pruritus (severe itching at injection site)
  6. Joint swelling
  7. Oedema peripheral (superficial swelling)
  8. Rash macular (small, flat red spots)
  9. Maternal exposure during pregnancy (use of substance during pregnancy)
  10. Injection site pain

40-49:

  1. Insomnia (sleeplessness)
  2. Muscle spasms (muscle contraction)
  3. Thirst
  4. Tinnitus (a ringing in the ears)
  5. Drug withdrawal syndrome (interfere with normal social, occupational, or other functioning. are not due to another medical condition, drug use, or discontinuation)
  6. Diarrhoea
  7. Drug dependence
  8. Fatigue (feeling of tiredness)
  9. Injection site cellulitis (injection site inflammation)
  10. Injection site erythema (redness at injection site)

50-59:

  1. Injection site pain
  2. Injection site erythema (redness at injection site)

60+:

n/a

What are the existing conditions these people have? *

  1. Drug Dependence: 10 people, 55.56%
  2. Stress And Anxiety: 4 people, 22.22%
  3. Pain: 2 people, 11.11%
  4. Drug Withdrawal Syndrome (interfere with normal social, occupational, or other functioning. are not due to another medical condition, drug use, or discontinuation): 2 people, 11.11%
  5. Sleep Disorder: 1 person, 5.56%
  6. Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 1 person, 5.56%
  7. Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 1 person, 5.56%
  8. Insomnia (sleeplessness): 1 person, 5.56%
  9. High Blood Pressure: 1 person, 5.56%
  10. Drowsiness: 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Cymbalta and Sublocade?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Cymbalta and Sublocade:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Cymbalta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Sublocade:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Cymbalta and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Sublocade and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on duloxetine hydrochloride and buprenorphine (the active ingredients of Cymbalta and Sublocade, respectively), and Cymbalta and Sublocade (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: